FI3373976T3 - Topikaalisia formulaatioita ja niiden käyttöjä - Google Patents

Topikaalisia formulaatioita ja niiden käyttöjä Download PDF

Info

Publication number
FI3373976T3
FI3373976T3 FIEP16864797.2T FI16864797T FI3373976T3 FI 3373976 T3 FI3373976 T3 FI 3373976T3 FI 16864797 T FI16864797 T FI 16864797T FI 3373976 T3 FI3373976 T3 FI 3373976T3
Authority
FI
Finland
Prior art keywords
formulation
hco
polyoxyl
weight
ophthalmic
Prior art date
Application number
FIEP16864797.2T
Other languages
English (en)
Finnish (fi)
Inventor
Sidney L Weiss
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Application granted granted Critical
Publication of FI3373976T3 publication Critical patent/FI3373976T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP16864797.2T 2015-11-10 2016-11-03 Topikaalisia formulaatioita ja niiden käyttöjä FI3373976T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562253569P 2015-11-10 2015-11-10
PCT/US2016/060391 WO2017083167A1 (en) 2015-11-10 2016-11-03 Topical formulations and uses thereof

Publications (1)

Publication Number Publication Date
FI3373976T3 true FI3373976T3 (fi) 2024-03-25

Family

ID=58695926

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16864797.2T FI3373976T3 (fi) 2015-11-10 2016-11-03 Topikaalisia formulaatioita ja niiden käyttöjä

Country Status (10)

Country Link
US (3) US20190231885A1 (enExample)
EP (2) EP3373976B1 (enExample)
JP (2) JP7793283B2 (enExample)
AU (1) AU2016351588A1 (enExample)
DK (1) DK3373976T3 (enExample)
ES (1) ES2974821T3 (enExample)
FI (1) FI3373976T3 (enExample)
PL (1) PL3373976T3 (enExample)
PT (1) PT3373976T (enExample)
WO (1) WO2017083167A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2887923T1 (sl) 2012-08-24 2023-09-29 Sun Pharmaceutical Industries Limited Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj
FI3373976T3 (fi) 2015-11-10 2024-03-25 Sun Pharmaceutical Ind Ltd Topikaalisia formulaatioita ja niiden käyttöjä
WO2017151657A1 (en) * 2016-02-29 2017-09-08 Ocular Technologies Sarl Topical cyclosporine-containing formulations and uses thereof
AU2021267217A1 (en) * 2021-08-20 2024-02-29 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1004520A1 (en) 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) * 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1296923B3 (en) 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
PL206018B1 (pl) 2001-10-19 2010-06-30 Isotechnika Inc Preparat farmaceutyczny, sposób jego wytwarzania, mikroemulsja i zastosowanie tego preparatu farmaceutycznego
US7030159B2 (en) 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
US6949664B2 (en) 2002-04-01 2005-09-27 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
DE60330154D1 (de) 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20040213782A1 (en) 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
WO2004096261A1 (es) 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050238589A1 (en) 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
DE602004017477D1 (de) 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
JP2008520739A (ja) 2004-11-19 2008-06-19 マーテック・バイオサイエンシーズ・コーポレーション 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法
RU2007149249A (ru) 2005-06-09 2009-07-20 Сантен Фармасьютикал Ко., Лтд (Jp) Глазные капли, содержащие рофлумиласт
CA2609251A1 (en) 2005-06-16 2006-12-28 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
WO2007090162A2 (en) 2006-01-31 2007-08-09 Martek Biosciences Corporation OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
JPWO2007126110A1 (ja) 2006-04-24 2009-09-17 ナノキャリア株式会社 低分子薬物内包ポリマーミセルの製造方法
WO2007136134A1 (ja) 2006-05-23 2007-11-29 Nanocarrier Co., Ltd. 疎水性薬物内包ポリマーミセルの製造方法
KR101363498B1 (ko) 2006-07-18 2014-02-14 나노캬리아 가부시키가이샤 생리활성 폴리펩티드 또는 단백질 내포 고분자 폴리머 미셀및 그 제조방법
EP2120920A4 (en) 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US9456980B2 (en) 2007-08-29 2016-10-04 Wakamoto Pharmaceutical Co., Ltd. Latanoprost-containing aqueous pharmaceutical composition
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
CN101990437A (zh) 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
KR20110010788A (ko) 2008-05-28 2011-02-07 알콘 리서치, 리미티드 자기보존 에멀젼
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
JP2012528857A (ja) 2009-06-02 2012-11-15 ウー，ニエン 純粋ｐｅｇ−脂質コンジュゲート
WO2010144194A1 (en) 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
CA2773597A1 (en) 2009-09-17 2011-03-24 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US9011861B2 (en) 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
MX2012012941A (es) 2010-05-07 2013-07-29 Sun Pharma Advanced Res Co Ltd Nuevas composiciones oftalmicas.
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
WO2013167865A1 (en) 2012-05-11 2013-11-14 Cipla Limited Pharmaceutical composition
SI2887923T1 (sl) 2012-08-24 2023-09-29 Sun Pharmaceutical Industries Limited Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
WO2015179527A1 (en) 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
US20150352176A1 (en) 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
FI3373976T3 (fi) 2015-11-10 2024-03-25 Sun Pharmaceutical Ind Ltd Topikaalisia formulaatioita ja niiden käyttöjä
WO2017083410A1 (en) 2015-11-12 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
WO2017151657A1 (en) 2016-02-29 2017-09-08 Ocular Technologies Sarl Topical cyclosporine-containing formulations and uses thereof
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
DK3373976T3 (da) 2024-04-02
US20240358840A1 (en) 2024-10-31
EP3373976A1 (en) 2018-09-19
EP4364810A3 (en) 2024-07-24
WO2017083167A1 (en) 2017-05-18
EP3373976A4 (en) 2019-05-22
EP4364810A2 (en) 2024-05-08
US12053528B2 (en) 2024-08-06
JP7669326B2 (ja) 2025-04-28
AU2016351588A1 (en) 2018-05-24
JP2018532809A (ja) 2018-11-08
PT3373976T (pt) 2024-04-02
PL3373976T3 (pl) 2024-06-24
JP2023012533A (ja) 2023-01-25
EP3373976B1 (en) 2024-01-03
US20190231885A1 (en) 2019-08-01
JP7793283B2 (ja) 2026-01-05
US20210268114A1 (en) 2021-09-02
ES2974821T3 (es) 2024-07-01

Similar Documents

Publication Publication Date Title
HRP20230559T1 (hr) Oftalmička formulacija polioksil lipida ili polioksil masne kiseline i tretman očnih stanja
CL2018003178A1 (es) Composición farmacéutica
FI3373976T3 (fi) Topikaalisia formulaatioita ja niiden käyttöjä
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
MD20140102A2 (ro) Compoziţii topice cu conţinut de fipronil şi permetrină şi metode de utilizare a lor
CO6311052A2 (es) Una microemulsion que comprende un ingrediente activo, un solvente y un surfactante no ionico y proceso para su preparación
BRPI0508933A (pt) composições para entrega tópica
BR112016025126A2 (pt) formulação líquida compreendendo composto neutralizante de gm-csf
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
RU2017109903A (ru) Композиции диклофенака натрия для местного применения
WO2015081904A3 (en) Polyurethaneurea solutions for compositions with active ingredients or fragrances
NI201900063A (es) Amidas aromáticas de ácido carboxílico
CO2021016449A2 (es) Composiciones terapéuticas estables en solventes polares aproticos y métodos de fabricación de las mismas
RU2016129193A (ru) Составы на основе берберина и их применение
BR112017017643A2 (pt) formulação farmacêutica tópica
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
MX2016014256A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
JP2010132607A (ja) アトピー性皮膚炎治療用軟膏剤
RU2012135798A (ru) Фармацевтическая композиция для лечения зуда кожи
JP6503627B2 (ja) 医薬液体組成物
AR086448A1 (es) Composicion farmaceutica que comprende drotaverina
JP6503626B2 (ja) 医薬組成物
RU2015132458A (ru) Пленочное покрытие препаративных форм, содержащих биологически активные вещества, суспензия для его формирования и способ его нанесения
RU2013148949A (ru) Местный состав, содержащий кортикостероид в качестве активного ингредиента